Skip to Main Content

Paper Details

Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Future Oncol
0
2023
Author NameAffiliation
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
Cora N SternbergEnglander Institute for Precision Medicine, Meyer Cancer Centre
Eleni EfstathiouMD Anderson Cancer Center
Fred SaadUniversity of Montreal Hospital Center
  • 1 - 4

Datasets

Release 1.2